Ensysce Biosciences Inc - Warrants (05/12/2019

(Warrants)
NEW
OTCPK:ENSCW (USA)   Warrants (05/12/2019)
$ 0.0023 -0.00023 (-9.2%) 10:23 AM EST
N/A
Volume:
34.55K
Avg Vol (2M):
0
Trade In:

Business Description

Ensysce Biosciences Inc
NAICS : 325412 SIC : 2834
ISIN : US2936021169

Share Class Description:

ENSCW: Warrants (05/12/2019)

Total Employee Number:

10
Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Name Current Vs Industry Vs History
Cash-To-Debt
3.03
Equity-to-Asset
-0.16
Debt-to-Equity
-0.72
Debt-to-EBITDA
-0.02
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
87.4
3-Year EPS without NRI Growth Rate
87.6
3-Year FCF Growth Rate
87.2
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.71
Quick Ratio
0.71
Cash Ratio
0.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-402.8
Shareholder Yield %
0.2
Name Current Vs Industry Vs History
ROE %
-560.44
ROA %
-256.38
ROIC %
-1699.11
3-Year ROIIC %
-320.44
ROC (Joel Greenblatt) %
-9645.9
ROCE %
-653.71
Years of Profitability over Past 10-Year
1
Moat Score
2
Tariff Resilience Score
5

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio
N/A
N/A
N/A
PE Ratio without NRI
N/A
N/A
N/A
FCF Yield %
-147800

GF Valueâ„¢

Ensysce Biosciences Inc Filings

Filing Date Document Date Form
No Filing Data

Ensysce Biosciences Inc Stock Events

Financials Calendars
Event Date Price ($)
General meeting for 2026 2026-12-23 09:00 In 180 days
Third quarter earnings results for 2026 2026-11-13 In 139 days
Second quarter earnings results for 2026 2026-08-13 In 47 days
First quarter earnings results for 2026 2026-05-15 --
First-ever European Pain Therapeutics Summit 2026-05-07 --
Annual report for 2025 2026-03-30 --
Fourth quarter earnings results for 2025 2026-03-30 --
General meeting for 2025 2025-12-23 09:00 --
Third quarter earnings results for 2025 2025-11-14 --
Second quarter earnings results for 2025 2025-08-13 --
Show
Entries

Guru Commentaries on OTCPK:ENSCW

No articles.

Articles on Ensysce Biosciences Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1